6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin

Abstract Objectives The aim of this study was to test the hypothesis that 6-month dual antiplatelet therapy (DAPT) is noninferior to 24-month DAPT in aspirin-sensitive patients. Background The ITALIC (Is There a Life for DES After Discontinuation of Clopidogrel) trial showed that rates of bleeding a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JACC. Cardiovascular interventions 2017-06, Vol.10 (12), p.1202-1210
Hauptverfasser:	Didier, Romain, MD, Morice, Marie Claude, MD, Barragan, Paul, MD, Noryani, Arif A.L., MD, Noor, Hussam A., MD, Majwal, Talib, MD, Hovasse, Thomas, MD, Castellant, Philippe, MD, Schneeberger, Michel, MD, Maillard, Luc, MD, PhD, Bressolette, Erwan, MD, Wojcik, Jaroslaw, MD, Delarche, Nicolas, MD, Blanchard, Didier, MD, Jouve, Bernard, MD, Ormezzano, Olivier, MD, Paganelli, Franck, MD, Levy, Gilles, MD, Sainsous, Joël, MD, Carrie, Didier, MD, Furber, Alain, MD, PhD, Berlan, Jacques, MD, Darremont, Olivier, MD, Le Breton, Hervé, MD, Lyuycx-Bore, Anne, MD, Gommeaux, Antoine, MD, Cassat, Claude, MD, Kermarrec, Alain, MD, Cazaux, Pierre, MD, Druelles, Philippe, MD, Dauphin, Raphael, MD, Armengaud, Jean, MD, Dupouy, Patrick, MD, Champagnac, Didier, MD, Ohlmann, Patrick, MD, Ben Amer, Hakim, MD, Kiss, Robert G., MD, Ungi, Irme, MD, Gilard, Martine, MD, PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiovascular drug-eluting stent(s) dual antiplatelet therapy Human health and pathology Life Sciences percutaneous coronary intervention
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Objectives The aim of this study was to test the hypothesis that 6-month dual antiplatelet therapy (DAPT) is noninferior to 24-month DAPT in aspirin-sensitive patients. Background The ITALIC (Is There a Life for DES After Discontinuation of Clopidogrel) trial showed that rates of bleeding and thrombotic events at 1 year were much the same with 6 versus 12 months of DAPT after percutaneous coronary intervention with second-generation drug-eluting stents. In this report, 2-year follow-up is presented. Methods In a multicenter randomized study, patients with confirmed nonresistance to aspirin undergoing drug-eluting stent implantation were allocated to 6 or 24 months of DAPT. The primary endpoint was a composite of death, myocardial infarction, urgent target vessel revascularization, stroke, and major bleeding at 12 months post–percutaneous coronary intervention. The secondary endpoints comprised the same composite endpoint at 24 months and each individual component. Results Overall, 2,031 patients from 70 centers were screened; 926 were randomized to 6-month and 924 to 24-month DAPT. Noninferiority was demonstrated for 6- versus 12-month DAPT, with an absolute risk difference of 0.11% (95% confidence interval: −1.04% to 1.26%; p = 0.0002). At 2 years, the composite endpoint was unchanged, at 3.5% for 6 months and 3.7% for 24 months (p = 0.79), and rates of myocardial infarction (1.3% vs. 1.0%; p = 0.51), stroke (0.6% vs. 0.8%; p = 0.77), and target vessel revascularization (1.0% vs. 0.3%; p = 0.09) were likewise similar. There was a trend toward higher mortality with longer DAPT (2.2% vs. 1.2%; p = 0.11). Four patients (0.4%) in the 24-month group and none in the 6-month group had major bleeding. Conclusions Two-year outcomes in the ITALIC trial confirmed the 1-year results and showed that patients receiving 6-month DAPT after percutaneous coronary intervention with second-generation drug-eluting stent have similar outcomes to those receiving 24-month DAPT.
ISSN:	1936-8798 1876-7605
DOI:	10.1016/j.jcin.2017.03.049